The GSK Code sets out the commitments GSK and our people make to get ahead together – so we can deliver on our ambition in the right way, bring our culture to life and make GSK an exciting and inspiring place to work.
The Anti-Bribery and Corruption (ABAC) Programme is part of GSK’s response to the threat and risk of bribery and corruption. The programme includes an ABAC Policy and Standard, which have been designed to help staff and external parties understand bribery and corruption risk, and their responsibilities to actively combat it.
The Financial Conflicts of Interest policy is a National Institutes of Health specific supplement to GSK’s Conflict of Interest and Anti-Bribery and Corruption policies to incorporate specific US federal regulatory requirements intended to promote and encourage transparency and avoid inappropriate use of US Public Health Service funding. This policy helps ensure that government funded research is conducted without bias and with the highest scientific and ethical standards by principle investigators.
Our annual Modern Slavery Act statement, as required by the Modern Slavery Act 2015 (“the Act”), provides details on the controls we have adopted to ensure that modern slavery and human trafficking do not take place in our supply chain or in any part of our business. The statement covers our financial year which runs from 1 January to 31 December.
- GSK Modern Slavery Act statement 2023 (PDF - 142kb)
- GSK Modern Slavery Act Statement 2022 (PDF - 194kb)
- GSK Modern Slavery Act Statement 2021 (PDF - 211kb)
- GSK Modern Slavery Act Statement 2020 (PDF - 191kb)
- GSK Modern Slavery Act Statement 2019 (PDF - 215kb)
- GSK Modern Slavery Act Statement 2018 (PDF - 145kb)
- GSK Modern Slavery Act Statement 2017 (PDF - 209kb)
As detailed in our Code of Conduct, we do not tolerate harassment, unwelcome, unreasonable or offensive behaviour or discrimination of any kind. Our Equal and Inclusive Treatment policy is designed to help our employees and complementary workers understand their role in ensuring GSK is a company where all employees are treated equally.
Our human resources and research and development activities involve the processing of “personal information”, including the transfer of that personal information internationally. We have adopted Binding Corporate Rules (BCRs) to enable us to make international transfers of personal information within our group of companies in compliance with data protection laws of the European Union, in particular the General Data Protection Regulation (Regulation 2016/679) (GDPR).
- GSK binding corporate rules (PDF - 216Kb)
- GSK binding corporate rules_Czech (PDF - 223Kb)
- GSK binding corporate rules_Danish (PDF - 205Kb)
- GSK binding corporate rules_Dutch (PDF - 208Kb)
- GSk binding corporate rules_Finnish (PDF - 170Kb)
- GSK binding corporate rules_French (PDF - 239Kb)
- GSk binding corporate rules_German (PDF - 211Kb)
- GSK binding corporate rules_Greek (PDF - 235Kb)
- GSK binding corporate rules_Italian(PDF - 220Kb)
- GSK binding corporate rules_Polish (PDF - 225)
- GSK binding corporate rules_Portuguese (PDF - 250Kb)
- GSK binding corporate rules_Spanish (PDF - 222Kb)
- GSK binding corporate rules_Swedish (PDF - 218Kb)
- Glaxosmithkline plc 2022 form sd conflict minerals disclosure (PDF - 131kb)
- Glaxosmithkline plc 2021 form sd conflict minerals disclosure (PDF - 89.9kb)
- Glaxosmithkline plc 2020 form sd conflict minerals disclosure (PDF - 121kb)
- Glaxosmithkline plc 2019 form sd conflict minerals disclosure (PDF- 161kb)
- Glaxosmithkline plc 2018 form sd conflict minerals disclosure (PDF - 289kb)
- Glaxosmithkline plc 2017 form sd conflict minerals disclosure (PDF - 241kb)
- Glaxosmithkline plc 2016 form sd conflict minerals disclosure (PDF - 1.2mb)
- Glaxosmithkline plc 2015 form sd conflict minerals disclosure (PDF - 130kb)
- Glaxosmithkline plc 2014 form sd conflict minerals disclosure (PDF - 122kb)
- GSK Euro Medium Term Note Programme – Supplementary Prospectus – December 2023
- GSK Euro Medium Term Note Programme – prospectus document – August 2023
- GSK Euro Medium Term Note Programme - Third Supplementary Prospectus November 2022
- GSK Euro Medium Term Note Programme – Further Supplementary Prospectus November 2022
- GSK Euro Medium Term Note Programme – Supplementary Prospectus November 2022 (PDF 110kb)
- GSK Euro Medium Term Note Programme – prospectus document – September 2022 (PDF - 1mb)
- GlaxoSmithKline Euro Medium Term Note Programme – prospectus document – December 2021 (PDF - 940kb)
- GlaxoSmithKline Euro Medium Term Note Programme – prospectus document – May 2021 (PDF - 923kb)
- Glaxosmithkline Euro Medium Term Note Programme – (PDF - 60kb) Supplementary Prospectus November 2020
- Glaxosmithkline Euro Medium Term Note Programme Prospectus Document 2020 (PDF - 1.5mb)
- GlaxoSmithKline Euro Medium Term Note Programme – Supplementary Prospectus 2020 (PDF - 73kb)
- Glaxosmithkline Euro Medium Term Note Programme – Prospectus Document 2019 (PDF - 1.3mb)
- GlaxoSmithKline Euro Medium Term Note Programme – Prospectus Document 2018 (PDF - 1.1mb)
- GlaxoSmithKline Euro Medium Term Note Programme – Prospectus Document 2017 (PDF - 506kb)
- GlaxoSmithKline Euro Medium Term Note Programme – Prospectus Document 2016 (PDF - 464kb)
- GlaxoSmithKline Euro Medium Term Note Programme – Prospectus Document 2015 (PDF - 470kb)
- GlaxoSmithKline Euro Medium Term Note Programme – Prospectus Document 2014 (PDF - 462kb)
- GlaxoSmithKline Euro Medium Term Note Programme – Prospectus Document 2013 (PDF - 3.4mb)
- GlaxoSmithKline Euro Medium Term Note Programme – Registration Document (PDF - 86kb)
- GlaxoSmithKline Euro Medium Term Note Programme – Prospectus Document (PDF - 3.4mb)
- GlaxoSmithKline Euro Medium Term Note Programme Supplementary Prospectus Document (PDF - 127kb)
- 2023 Half Year Results and Interim Management Report Glaxosmithkline Capital plc (PDF - 3.3mb)
- 2022 Annual Report GlaxoSmithKline Capital plc (PDF - 447)
- 2022 Half Year Results and Interim Management Report Glaxosmithkline Capital Plc (PDF - 325kb)
- 2021 Annual Report GlaxoSmithKline Capital plc (PDF - 245kb)
- 2020 Annual Report Glaxosmithkline Capital Plc (PDF - 430kb)
- 2020 Half Year Results And Interim Management Report Glaxosmithkline Capital Plc (PDF - 229kb)
- 2019 Annual Report GlaxoSmithKline Capital plc (PDF - 596kb)
- 2019 Half Year Results And Interim Management Report Glaxosmithkline Capital Plc (PDF - 188kb)
- 2018 Annual Report GlaxoSmithKline Capital plc (PDF - 420kb)
- 2018 Half Year Results And Interim Management Report Glaxosmithkline Capital Plc (PDF - 427kb)
- 2017 Annual Report GlaxoSmithKline Capital plc (PDF - 741kb)
- 2017 Half Year Results and Interim Management Report GlaxoSmithKline Capital plc (PDF 301kb)
- 2016 Annual Report GlaxoSmithKline Capital plc (PDF - 7.6mb)
- 2016 Half Year Results and Interim Management Report GlaxoSmithKline Capital plc (PDF - 360kb)
- 2015 Annual Report GlaxoSmithKline Capital plc (PDF - 640kb)
- 2015 Half Year Results and Interim Management Report GlaxoSmithKline Capital plc (PDF - 342kb)
- 2014 Annual Report GlaxoSmithKline Capital plc (PDF - 7.9mb)
- 2014 Half Year Results and Interim Management Report GlaxoSmithKline Capital plc (PDF - 68kb)
- 2013 Annual Report GlaxoSmithKline Capital plc (PDF - 331kb)
- 2013 Half Year Results and Interim Management Report GlaxoSmithKline Capital plc (PDF - 2.1mb)
- 2012 Annual Report GlaxoSmithKline Capital plc (PDF - 540kb)
- 2012 Half Year Results and Interim Management Report GlaxoSmithKline Capital plc (PDF - 182kb)
- 2011 Annual Report GlaxoSmithKline Capital plc (PDF - 617kb
- 2011 Half Year Results and Interim Management Report GlaxoSmithKline Capital plc (PDF - 301kb)
- 2010 Annual Report GlaxoSmithKline Capital plc (PDF - 4.9mb)
- 2009 Annual Report GlaxoSmithKline Capital plc (PDF - 2.9mb)
- 2008 Annual Report GlaxoSmithKline Capital plc (PDF - 3.5mb)
GSK is committed to protecting people and the environment, moving towards our sustainability ambitions and promoting wellbeing and the safety of our people. Our Environment, Health and Safety policy sets out our approach to managing EHS risks and creating opportunities across our organisation to fulfil our EHS protection commitments, both internally and externally.
Occupational Health and Safety is part of EHS at GSK and information on our management systems can be found in our Occupational Health and Safety report.
